Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IHV01 and DNA CON-S env HIV Vaccine Safety and Immunogenicity
NCT03505060Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2019
- Primary completion
- May 2019
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing DNA CON-S env + IHV01 with Placebo (2 arms). Primary endpoints: Frequency of local and systemic reactogenicity signs and symptoms, Distribution of values of laboratory measures of safety at Month 12 and 3 more. Planned start Jan 2019; status: withdrawn.
02
Drugs
IHV01
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03505060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505060.